These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 20959810)

  • 21. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
    Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
    J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.
    Naik S; Nace R; Barber GN; Russell SJ
    Cancer Gene Ther; 2012 Jul; 19(7):443-50. PubMed ID: 22522623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy.
    Kottke T; Tonne J; Evgin L; Driscoll CB; van Vloten J; Jennings VA; Huff AL; Zell B; Thompson JM; Wongthida P; Pulido J; Schuelke MR; Samson A; Selby P; Ilett E; McNiven M; Roberts LR; Borad MJ; Pandha H; Harrington K; Melcher A; Vile RG
    Nat Commun; 2021 Mar; 12(1):1930. PubMed ID: 33772027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.
    Rommelfanger DM; Offord CP; Dev J; Bajzer Z; Vile RG; Dingli D
    Gene Ther; 2012 May; 19(5):543-9. PubMed ID: 21918546
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RIG-I-mediated innate immune signaling in tumors reduces the therapeutic effect of oncolytic vesicular stomatitis virus.
    Zhang P; Han X; Tan W; Chen D; Sun Q
    Thorac Cancer; 2023 Jan; 14(3):246-253. PubMed ID: 36447430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
    Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
    Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
    Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo.
    Cary ZD; Willingham MC; Lyles DS
    J Virol; 2011 Jun; 85(12):5708-17. PubMed ID: 21450822
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma.
    Murphy AM; Besmer DM; Moerdyk-Schauwecker M; Moestl N; Ornelles DA; Mukherjee P; Grdzelishvili VZ
    J Virol; 2012 Mar; 86(6):3073-87. PubMed ID: 22238308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
    Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
    Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigating Macrophages Plasticity Following Tumour-Immune Interactions During Oncolytic Therapies.
    Eftimie R; Eftimie G
    Acta Biotheor; 2019 Dec; 67(4):321-359. PubMed ID: 31410657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms.
    Ahmed M; Mitchell LM; Puckett S; Brzoza-Lewis KL; Lyles DS; Hiltbold EM
    J Virol; 2009 Apr; 83(7):2962-75. PubMed ID: 19144711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.
    Rommelfanger DM; Wongthida P; Diaz RM; Kaluza KM; Thompson JM; Kottke TJ; Vile RG
    Cancer Res; 2012 Sep; 72(18):4753-64. PubMed ID: 22836753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type III interferon attenuates a vesicular stomatitis virus-based vaccine vector.
    Guayasamin RC; Reynolds TD; Wei X; Fujiwara M; Robek MD
    J Virol; 2014 Sep; 88(18):10909-17. PubMed ID: 25008938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy.
    Durham NM; Mulgrew K; McGlinchey K; Monks NR; Ji H; Herbst R; Suzich J; Hammond SA; Kelly EJ
    Mol Ther; 2017 Aug; 25(8):1917-1932. PubMed ID: 28578991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.